Search

Orcigesic

Orcigesic

Manufacturer:

Sunward

Distributor:

Apex Pharma Marketing
Concise Prescribing Info
Contents
Per 250/35 mg cap Mefenamic acid 250 mg, orphenadrine citrate 35 mg. Per 250/35 mg tab Mefenamic acid 250 mg, orphenadrine citrate 35 mg
Indications/Uses
Anti-inflammatory, analgesic & anti-pyretic. Relaxes & inhibits striated muscle spasm.
Dosage/Direction for Use
Adult & childn >14 yr Initially 2 cap/tab followed by 1 cap/tab every 6 hr as needed. Max duration: 1 wk.
Click to view Orcigesic detailed prescribing information
Administration
Should be taken with food.
Contraindications
Hypersensitivity to aspirin or other NSAIDs. Do not give to patients in whom these drugs induce symptoms of bronchospasm, allergic rhinitis or urticaria. Not to be used in patients w/ glaucoma, achalasia, prostatic hypertrophy, bladder neck obstruction or myasthenia gravis. Childn <14 yr. Mefenamic acid: Patients w/ active ulceration or chronic inflammation of either upper or lower GIT; avoid in patients w/ pre-existing renal disease.
Click to view Orcigesic detailed prescribing information
Warnings
For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Orcigesic detailed prescribing information
Special Precautions
Contains tartrazine which may cause allergic type reactions (including bronchial asthma) in certain susceptible individuals. Pregnancy; not recommended in late pregnancy due to foetal CV system effects; may cause foetal renal dysfunction leading to oligohydramnios & neonatal renal impairment (in some cases) during use at about 20 wk gestation or later in pregnancy.
Adverse Reactions
Diarrhoea, nausea w/ or w/o vomiting & abdominal pain. Leukopenia, eosinophilia, pancytopenia, thrombocytopenic purpura, agranulocytosis & bone marrow hypoplasia; drowsiness, dizziness, nervousness, headache, blurred vision & insomnia; urticaria, rash & facial oedema; papillary necrosis, renal failure, haematuria & dysuria; eye irritation, ear pain, perspiration & mild hepatic toxicity, mouth dryness w/ difficulty in swallowing, thirst, pupil dilatation w/ loss of accommodation & photophobia, increased IOP, skin flushing, transient bradycardia followed by tachycardia w/ palpitations & arrhythmias, difficult micturition & constipation. Mefenamic acid: Auto-immune hemolytic anaemia (continuous administration for ≥12 mth).
Click to view Orcigesic detailed prescribing information
Drug Interactions
Mefenamic acid: May prolong prothrombin time w/ anti-coagulants. Orphenadrine citrate: Induced enzymatic systems involving metabolism of aminopyrine, steroidal contraceptives, griseofulvin, hexobarbital & phenylbutazone; potentiate other anticholinergics.
Click to view Orcigesic detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Orcigesic detailed prescribing information
Storage
View Orcigesic storage conditions for details to ensure optimal shelf-life.
Description
View Orcigesic description for details of the chemical structure and excipients (inactive components).
Action
View Orcigesic mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Muscle Relaxants
ATC Classification
M03BC51 - orphenadrine, combinations ; Belongs to the class of ethers. Used as centrally-acting muscle relaxants.
Presentation/Packing
Form
Orcigesic tab
Packing/Price
10 × 10 × 10's
Form
Orcigesic cap
Packing/Price
10 × 10 × 10's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in